Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
Why Is Argenx (ARGX) Stock Down 25% Today?
02:38pm, Wednesday, 20'th Dec 2023
Shares of biotechnology specialist Argenx (NASDAQ: ARGX ) — which focuses on addressing severe autoimmune diseases – suffered a hefty decline on Wednesday following a clinical disappointment. Its
This biotech stock is down 25% on Wednesday: find out why
11:44am, Wednesday, 20'th Dec 2023
Argenx SE (NASDAQ: ARGX) says a late-stage trial of its candidate drug for an autoimmune condition failed to meet the primary or secondary endpoints. Its shares are down 25% at writing.
Argenx stock dives by a third after late-stage trial didn't meet goals
04:16am, Wednesday, 20'th Dec 2023
Argenx stock ARGX, -33.70% ARGX, -0.64% lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of using efgartigi
These 2 Stocks Are Falling in a Fading Rally
08:51am, Tuesday, 28'th Nov 2023
Stock markets looked ready to ease lower Tuesday morning after big gains earlier in the month. Zscaler stock fell back even with strong results in its fiscal first quarter.
Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth
01:16pm, Monday, 06'th Nov 2023
In the world of investing, it's often the hidden gems that yield the most extraordinary returns. While Wall Street keeps a watchful eye on the giants, lesser-known stocks are quietly charting a course
argenx to Present at Upcoming Investor Conferences
02:00am, Wednesday, 01'st Nov 2023
November 1, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda
argenx SE (ARGX) Q3 2023 Earnings Call Transcript
03:32pm, Tuesday, 31'st Oct 2023
argenx SE (NASDAQ:ARGX ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corporate Communications and IR Tim Van Hauwermeiren - C
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
01:00am, Tuesday, 24'th Oct 2023
October 24, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda
argenx: Efgartigimod Is Not Just A Drug, A Cornerstone
01:07am, Tuesday, 17'th Oct 2023
argenx exhibits robust financials with a Q2 YoY net sales surge to $269.3M and liquidity of $2.0B but faces increasing operating costs and R&D expenditures. Efgartigimod, ARGX's primary asset, shows h
Argenx's 28% Surge & Promising Product Propel Investor Confidence
07:11am, Monday, 25'th Sep 2023
The stock gapped up nearly 28% on July 17, after announcing better-than-expected results from a clinical trial of its treatment for patients suffering from a progressive condition that affects muscle
This New S&P 500 Entrant Leads 5 Stocks Near Buy Points
09:00am, Saturday, 16'th Sep 2023
DraftKings and new S&P 500 entrant Airbnb lead a watch list of stocks poised to make moves if the stock market can find its footing.
argenx to Present at Upcoming Investor Conferences
01:00am, Wednesday, 30'th Aug 2023
August 30 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to
Is Argenx Stock a Buy Now?
10:00am, Monday, 31'st Jul 2023
Argenx recently reported positive news from a clinical trial for its lead medicine. The company could be looking at many more approvals for this therapy.
Why Shares of Argenx Jumped This Week
01:17pm, Friday, 21'st Jul 2023
Argenx has only two approved therapies, Vyvgart and Vyvgart Hytrulo. Vyvgart Hytrulo fared well in a trial to treat adults with chronic inflammatory demyelinating polyneuropathy, an autoimmune disorde
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
01:00am, Thursday, 20'th Jul 2023
July 20 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda
